期刊
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
卷 136, 期 12, 页码 1482-1491出版社
COLL AMER PATHOLOGISTS
DOI: 10.5858/arpa.2012-0508-RA
关键词
-
Context.-The advent of genotype-based therapy and predictive biomarkers for lung cancer has thrust the pathologist into the front lines of precision medicine for this deadly disease. Objective.-To provide the clinical background, current status, and future perspectives of molecular targeted therapy for lung cancer patients, including the pivotal participation of the pathologist. Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature. Conclusions.-First-generation tyrosine kinase inhibitors have produced clinical response in a limited number of non-small cell lung cancers demonstrated to have activating mutations of epidermal growth factor receptor or anaplastic lymphoma kinase rearrangements with fusion partners. Patients treated with first-generation tyrosine kinase inhibitors develop acquired resistance to their therapy. Ongoing investigations of second-generation tyrosine kinase inhibitors and new druggable targets as well as the development of next-generation genotyping and new antibodies for immunohistochemistry promise to significantly expand the pathologist's already crucial role in precision medicine of lung cancer. (Arch Pathol Lab Med. 2012; 136: 1482-1491; doi: 10.5858/arpa.2012-0508-RA)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据